CoChat

Therapeutic Potential of Small Molecules and Engineered Proteins

Open access
Gurevich, Eugenia V., Gurevich, Vsevolod V. · 2014 · Handbook of Experimental Pharmacology
Cited by 92

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Virtually all currently used therapeutic agents are small molecules, largely because the development and delivery of small molecule drugs is relatively straightforward. Small molecules have serious limitations: drugs of this type can be fairly good enzyme inhibitors, receptor ligands, or allosteric modulators. However, most cellular functions are mediated by protein interactions with other proteins, and targeting protein–protein interactions by small molecules presents challenges that are unlikely to be overcome with these compounds as the only tools. Recent advances in gene delivery techniques and characterization of cell type-specific promoters open the prospect of using reengineered signaling-biased proteins as next-generation therapeutics. The first steps in targeted engineering of proteins with desired functional characteristics look very promising. As quintessential scaffolds that act strictly via interactions with other proteins in the cell, arrestins represent a perfect model for the development of these novel therapeutic agents with enormous potential: custom-designed signaling proteins will allow us to tell the cell what to do and when to do it in a way it cannot disobey.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-3-642-41199-1_1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • The druggable genome

    Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 3×

    “For example, in case of GPCRs, which are targeted by >30 % of clinically used drugs (Hopkins and Groom 2002), the agonists promote receptor interactions with heterotrimeric G proteins (Samama et al. 1993), then GPCR kinases (GRKs) (Gurevich et al. 2012), and then arrestins (Gurevich and Gurevich…”
    BackgroundInfluential
  • Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis

    Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×

    “was delivered to the pigment epithelium of Leber’s congenital amaurosis patients carrying loss-of-function mutations in this protein (Cideciyan et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008) demonstrate that gene delivery methods are ready for use today, not in the distant future (Cid…”
    Background
  • Effect of gene therapy on visual function in Leber’s congenital amaurosis

    Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×

    “was delivered to the pigment epithelium of Leber’s congenital amaurosis patients carrying loss-of-function mutations in this protein (Cideciyan et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008) demonstrate that gene delivery methods are ready for use today, not in the distant future (Cid…”
    Background
  • Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

    Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×

    “…to the pigment epithelium of Leber’s congenital amaurosis patients carrying loss-of-function mutations in this protein (Cideciyan et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008) demonstrate that gene delivery methods are ready for use today, not in the…”
    Background
  • Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy

    Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256 · cited 1×

    “…congenital amaurosis patients carrying loss-of-function mutations in this protein (Cideciyan et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008) demonstrate that gene delivery methods are ready for use today, not in the distant future (Cideciyan 2010; Cao et al. 2011).”
    Background

Show all 5 references

Cited by

See all 92

Metadata

Authors
Gurevich, E. V., & Gurevich, V. V.
Venue
Handbook of Experimental Pharmacology
Published
2013-11-05
Volume
219
Pages
1-12
ISSN
  • 0171-2004 (ISSN-L)
  • 1865-0325
OpenAlex
W78375872
Cited by
92
References
5
FWCI
1.31
Type
book chapter
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Potential of Small Molecules and Engineered Proteins. https://app.cochat.ai/papers/10.1007/978-3-642-41199-1_1
The paper
Gurevich, E. V., & Gurevich, V. V. (2014). Therapeutic Potential of Small Molecules and Engineered Proteins. Handbook of Experimental Pharmacology. https://doi.org/10.1007/978-3-642-41199-1_1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.